戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 exclusive use of the VH 4-34 gene segment in cold agglutinins.
2 -three percent of pretransplant patients had cold agglutinins.
3 europathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies.
4 oplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) is a rare s
5                               In conclusion, cold agglutinins are common in liver transplant patients
6 ne hemolytic anemia in which autoantibodies (cold agglutinins) bind to red blood cells (RBCs) at low
7 utoantibodies from a number of patients with cold agglutinin (CA) disease include both IgM hexamers a
8                              Essentially all cold agglutinins (CA) with red blood cell I/i specificit
9  prevents induction of in vitro hemolysis by cold agglutinins (CA).
10 ing renal transplantation in the presence of cold agglutinins can cause graft malfunction.
11                                              Cold agglutinin disease (CAD) and warm antibody autoimmu
12 We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countri
13                              Primary chronic cold agglutinin disease (CAD) is a well-defined clinicop
14                         One such disorder is cold agglutinin disease (CAD), an autoimmune hemolytic a
15                                           In cold agglutinin disease (CAD), immunoglobulin M autoanti
16 nation fludarabine and rituximab for chronic cold agglutinin disease (CAD).
17 have seen great progress in the treatment of cold agglutinin disease (CAD).
18 tified 89 patients from our institution with cold agglutinin disease from 1970 through 2012.
19                                              Cold agglutinin disease is a difficult-to-treat autoimmu
20                                              Cold agglutinin disease is a rare and poorly understood
21                                              Cold agglutinin disease is a rare autoimmune hemolytic a
22                            Ten patients with cold agglutinin disease participated in the phase 1b com
23                    Seven of 10 patients with cold agglutinin disease responded with a hemoglobin incr
24 ns, IgM red blood cell autoantibodies, cause cold agglutinin disease with hemolysis and microvascular
25 en) on erythrocytes and B lymphocytes, cause cold agglutinin disease, and are carried by 5% of naive
26 include paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, hemolytic uremic syndrome, neph
27 us, immune thrombocytopenic purpura, chronic cold agglutinin disease, IgM-mediated neuropathies and m
28 bition has also shown efficacy and safety in cold agglutinin disease, primarily with the C1s inhibito
29 mplement-mediated hemolysis in patients with cold agglutinin disease, significantly increasing hemogl
30 valuation and treatment improves outcomes in cold agglutinin disease.
31 olysis of riliprubart in adult patients with cold agglutinin disease.
32 l neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or evidence of disease transfor
33 l neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or transformed disease should b
34                     However, the presence of cold agglutinins does not impact on outcome after liver
35 eventing CP activation, TNT003 also prevents cold agglutinin-driven generation of anaphylatoxins.
36 nation of the crystal structure of an anti-I cold agglutinin has revealed a hydrophobic patch in FR1
37                                              Cold agglutinins, IgM red blood cell autoantibodies, cau
38 ured the pretransplant presence and titer of cold agglutinins in 327 primary liver allograft recipien
39                 The IgM antibodies were also cold agglutinins in 50% of cases.
40 fference between recipients with and without cold agglutinins in usage of blood products, postoperati
41 ent samples and showed that TNT003 prevented cold agglutinin-mediated deposition of complement opsoni
42 rine protease C1s, on CP activity induced by cold agglutinins on human RBCs.
43                       However, the impact of cold agglutinins on the outcome of liver transplantation
44 M(low) IgD+ IGHV4-34+ B cells and removal of cold agglutinin self-reactivity by hypermutation, often
45                                   Therapy of cold agglutinin syndrome often is unsatisfactory.
46 mune hemolytic anemia of warm antibody type, cold agglutinin syndrome, paroxysmal cold hemoglobinuria
47                           The monoclonal IgM cold agglutinins that bind to the I/i carbohydrate Ags o
48                                              Cold agglutinins were identified in 15 (34%) patients.
49                                              Cold agglutinins were more common in patients with viral
50 to coat human red blood cells, sensitized by cold agglutinins, with C4 and C3.